XML 44 R31.htm IDEA: XBRL DOCUMENT v3.22.1
SHARE-BASED AWARDS
12 Months Ended
Dec. 31, 2021
SHARE-BASED AWARDS  
SHARE-BASED AWARDS

23.   SHARE-BASED AWARDS

On October 16, 2008, the Board of Directors adopted the 2008 Share Incentive Plan (the “2008 Share Incentive Plan”). The 2008 Share Incentive Plan provides for the granting of options, share appreciation rights, or other share based awards to key employees, directors or consultants, which was subsequently amended on November 17, 2009 and November 26, 2011 to increase the number of ordinary shares available for grant under the plan. The total number of the Company’s ordinary shares that may be issued under the 2008 Share Incentive Plan is up to 13,218,000 ordinary shares.

Share options

On February 18, 2014, the Company granted options to purchase 3,479,604 ordinary shares to its employees at an exercise price of $2.04 per share that have a contractual life of eight years and vest over four equal installments on the first, second, third, and fourth anniversary of the grant date. The Company recognizes the compensation expense on a straight-line basis over the requisite service period for the entire award. The Company calculated the estimated grant date fair value of the share options granted on February 18, 2014, using a Binomial Tree Model, with key assumptions as follows.

    

February 18, 2014

 

Risk-free interest rate

 

2.33

%

Dividend yield

 

5

%

Exercise multiple

 

2.5

Expected volatility range

 

39.03

%

The risk-free rate was based on the US Treasury bond yield curve in effect at the time of grant for periods corresponding with the expected term of the option. The dividend yield was estimated based on the average of historical dividend yields of the Company. The volatility assumption was estimated based on the historical price volatility of ordinary shares of comparable companies in the health care industry.

The following table summarizes employee share options activities for the year ended December 31, 2021:

Weighted

Weighted-

Weighted

Average

Average

Average

Remaining

Aggregate

Number of

Exercise

Grant-date

Contractual

Intrinsic

Share Options Granted to Employees

    

Shares

    

Price

    

Fair Value

    

Term (Years)

    

Value

Outstanding, January 1, 2021

 

2,774,229

 

US$

2.04

 

US$

0.65

 

1.13

 

Lapsed

 

(116,283)

 

US$

2.04

 

US$

0.65

 

 

Outstanding, December 31, 2021

 

2,657,946

 

US$

2.04

 

US$

0.65

 

0.13

 

Exercisable at December 31, 2021

 

2,657,946

 

US$

2.04

 

US$

0.65

 

0.13

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the fair value of the Company’s shares that would have been received by the option holders if all in-the-money options had been exercised on the issuance date.

There were no options exercised for the years ended December 31, 2019, 2020 and 2021.

As of December 31, 2021, unrecognized share-based compensation cost related to share options was nil.

Restricted shares

On February 18, 2014, July 1, 2014 and August 1, 2014, the Company granted 1,370,250, 21,132 and 69,564 restricted shares of the Company (“Restricted Shares”) to the employees of the Company, respectively. The Restricted Shares have a service condition where the grantees can remove restriction on 25% of total number of Restricted Shares on annual basis over a four-year period ending the fourth anniversary of the grant date.

The Group did not grant any Restricted Shares in 2015 and 2016.

On August 7, 2017, August 8, 2017, September 13, 2017 and October 2, 2018, the Company granted 1,453,950, 3,319,200, 45,000 and 5,992,605 Restricted Shares to the employees of the Company, respectively. The Restricted Shares have a service condition where the grantees can remove restriction on 25% of total number of restricted shares on annual basis over a four-year period ending the fourth anniversary of the grant date.

Fair Value per Share

at the Grant

Grant Date

    

Number of Awards

    

date (US$)

February 18, 2014

 

1,370,250

 

1.93

July 1, 2014

 

21,132

 

2.35

August 1, 2014

 

69,564

 

2.44

August 7, 2017

 

1,453,950

 

1.33

August 8, 2017

 

3,319,200

 

1.34

September 13, 2017

 

45,000

 

1.33

October 2, 2018

 

5,992,605

 

1.19

The Company recognizes the compensation expense on a straight-line basis over the requisite service period for the entire award. Restricted Shares activity for the year ended December 31, 2021 was as follows:

    

    

Weighted

Numbers

average grant

of shares

date fair value

RMB

US$

Outstanding, January 1, 2021

 

11,033,064

 

1.31

Granted

 

 

Forfeited

 

(134,775)

 

1.22

Exercised

 

 

Outstanding, December 31, 2021

 

10,898,289

 

1.31

Exercisable, December 31, 2021

5,084,184

1.45

Expected to vest, December 31, 2021

 

5,814,105

 

1.19

As of December 31, 2021, unrecognized share-based compensation cost related to Restricted Shares was RMB8,391 (US$1,301) which is expected to be recognized over a weighted-average vesting period of 0.4 years.

The share-based compensation expense of the share options and Restricted Shares granted to employees for the years ended December 31, 2019, 2020 and 2021 is as follows:

For the Years ended December 31, 

2019

2020

2021

2021

    

RMB

    

RMB

    

RMB

    

US$

General and administrative expenses

 

17,673

 

17,553

 

12,565

 

1,972

Selling expenses

 

2,920

 

3,068

 

2,115

 

332

 

20,593

 

20,621

 

14,680

 

2,304